Head-to-head · WeighScore
NuuVim vs WellMedr
The verdict
NuuVim takes it — 70.6/100 to 63.2/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | WellMedr |
|---|---|---|
| WeighScore | 70.6/100 | 63.2/100 |
| Grade | C | C |
| Scorecard rank | #117 | #218 |
| Semaglutide | $79/mo (all doses, 3-mo plan, new patients only, compounded) | $59/mo on a 12-month plan |
| Tirzepatide | $133/mo (all doses, 3-mo plan, new patients only, compounded) | $99/mo on a 12-month plan |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #117 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
Graded #218 · C
Strengths
- Eight named microdose products across oral and injectable routes, each with its formulation published — a real low-dose line, not a smaller amount of a standard plan
- States its dose basis outright on the tirzepatide plan: "Same price regardless of dosage"
- Publishes what a "month" contains — both plans say "shipped every 4 weeks" on the plan card itself
- Names the treating clinical group in its telehealth consent: OpenLoop Health, Inc. and its state professional corporations
- Names both halves of the supply chain: OpenLoop Health, Inc. as the medical group and "Mycelium Pharmacy — our U.S.-licensed fulfillment pharmacy" as the dispenser — most compounded sellers name neither
- Puts the compounding caveat on the pricing page, not in a footer: compounded medications are "regulated by state Boards of Pharmacy, but are not evaluated by the FDA for safety or efficacy", with explicit thyroid C-cell tumor and MTC warnings
- Offers FDA-approved brand product — Ozempic from $1,399, Zepbound from $1,599 — for anyone who decides against compounded
Where it loses points
- The microdose page headlines "ZERO Side Effects", subheaded "Zero side effct for 70%+ of members" (their typo) — an unqualified claim no evidence supports, on a page that carries no safety notice at all — the thyroid C-cell tumor warning is on the pricing page, not this one
- ITS FAQ SAYS THE MEDICATIONS ARE FDA APPROVED. Asked "Are these medications FDA approved?", the page answers "Yes. We only work with U.S. licensed pharmacies that dispense FDA-approved medications" — while the footer of that same page says they are "not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality". A buyer asking the one regulatory question that matters is told the opposite of the truth
- TWO DIFFERENT BILLING CYCLES ARE PUBLISHED. The plan cards say "shipped every 4 weeks" — 13 charges a year — while the refund policy says the subscription "will automatically renew every 21 days", which is about 17. Which one your card sees is not knowable from the site
- The advertised $59 is a twelve-month rate — the banner reads "Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life". It names only that figure; the $99 tirzepatide card carries no such condition and says "Cancel or change anytime". Yet no standing month-to-month rate is published for either molecule
- A "month" is four weeks on both plans, so a year is 13 charges rather than 12 — about 8.6% more than the monthly label implies
- Six of the eight microdose products publish no price at all; the two that do both show $199/month regardless of formulation
- The semaglutide plan makes no statement about dose basis in either direction, so whether a low dose costs less there is simply unknown
- Two discounts stack — "$200 OFF Every Month" and a separate "$150 off for Life" — and neither reverses into a standing rate
- The results carousel is disclosed as "Inspired by real patient success stories in similar Telehealth programs", so those figures are not WellMedr patients
- The top bar advertises "FDA-regulated pharmacies" — a claim about the pharmacy, not the drug
- The pharmacy is named only in the privacy policy — not on the pricing page, the microdose page or anywhere a buyer would look for it
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.